Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'INTRAVESICAL THERAPY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 84 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kim, JC; Steinberg, GD
      Medical management of patients with refractory carcinoma in situ of the bladder

      DRUGS & AGING
    2. Bernardini, S; Chabannes, E; Bittard, H
      Value of p53 in the clinical management of bladder cancer.

      PROGRES EN UROLOGIE
    3. Kuromatsu, I; Matsuo, K; Takamura, S; Kim, G; Takebe, Y; Kawamura, J; Yasutomi, Y
      Induction of effective antitumor immune responses in a mouse bladder tumormodel by using DNA of an alpha antigen from mycobacteria

      CANCER GENE THERAPY
    4. Sekine, H; Ohya, K; Kojima, S; Igarashi, K; Fukui, I
      Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder

      INTERNATIONAL JOURNAL OF UROLOGY
    5. Baselli, EC; Greenberg, RE
      Maintenance therapy for superficial bladder cancer

      ONCOLOGY-NEW YORK
    6. Bochner, BH; Skinner, DG
      Maintenance therapy for superficial bladder cancer - The Baselli/Greenbergarticle reviewed

      ONCOLOGY-NEW YORK
    7. Jocham, D; Durek, C
      Treatment of superficial tumors of the urinary bladder

      UROLOGE A
    8. Kim, JC; Steinberg, GD
      The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder

      JOURNAL OF UROLOGY
    9. Choudry, GA; Stewart, PAH; Double, JA; Krul, MRL; Naylor, B; Flannigan, GM; Shah, TK; Brown, JE; Phillips, RM
      A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9

      BRITISH JOURNAL OF CANCER
    10. Lamm, DL
      Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer

      CLINICAL INFECTIOUS DISEASES
    11. Audigier, C; Nesme, P; Perol, M; Guerin, JC
      A rare lung complication of intra-bladder BCG therapy

      REVUE DES MALADIES RESPIRATOIRES
    12. Lamm, DL; Allaway, M
      Current trends in bladder cancer treatment

      ANNALES CHIRURGIAE ET GYNAECOLOGIAE
    13. Schmitz-Drager, BJ; Goebell, PJ; Ebert, T; Fradet, Y
      p53 immunohistochemistry as a prognostic marker in bladder cancer - Playground for urology scientists?

      EUROPEAN UROLOGY
    14. Linn, JF; Black, P; Derksen, K; Rubben, H; Thuroff, JW
      Keyhole limpet haemocyanin in experimental bladder cancer

      EUROPEAN UROLOGY
    15. Jurincic-Winkler, CD; Metz, KA; Beuth, J; Klippel, KF
      Keyhole limpet hemocyanin for carcinoma in situ of the bladder: A long-term follow-up study

      EUROPEAN UROLOGY
    16. Bohle, A
      BCG's mechanism of action - Increasing our understanding

      EUROPEAN UROLOGY
    17. Lamm, DL
      Preventing progression and improving survival with BCG maintenance

      EUROPEAN UROLOGY
    18. Malmstrom, PU
      Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience

      EUROPEAN UROLOGY
    19. Durek, C; Rusch-Gerdes, S; Jocham, D; Bohle, A
      Sensitivity of BCG to modern antibiotics

      EUROPEAN UROLOGY
    20. Rischmann, P; Desgrandchamps, F; Malavaud, B; Chopin, DK
      BCG intravesical instillations: Recommendations for side-effects management

      EUROPEAN UROLOGY
    21. Khandaker, MH; Kadhim, SA; Ichim, TE; Howson-Jan, K; Chin, J; Singhal, SK
      Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed

      ANTICANCER RESEARCH
    22. Marchetti, A; Wang, LP; Magar, R; Grossman, HB; Lamm, DL; Schellhammer, PF; Erwin-Toth, P
      Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin

      CLINICAL THERAPEUTICS
    23. Zlotta, AR; Schulman, CC
      Biological markers in superficial bladder tumors and their prognostic significance

      UROLOGIC CLINICS OF NORTH AMERICA
    24. Zhang, GJ; Crist, SA; McKerrow, AK; Xu, Y; Ladehoff, DC; See, WA
      Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha 5 beta 1 fibronectin receptor

      JOURNAL OF UROLOGY
    25. Knemeyer, I; Wientjes, MG; Au, JLS
      Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    26. Crew, JP
      Vascular endothelial growth factor: An important angiogenic mediator in bladder cancer

      EUROPEAN UROLOGY
    27. Syrigos, KN; Deonarian, DP; Epenetos, AA
      Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer

      HYBRIDOMA
    28. Hurle, R; Losa, A; Manzetti, A; Lembo, A
      Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients

      UROLOGY
    29. Durek, C; Rusch-Gerdes, S; Jocham, D; Bohle, A
      Interference of modern antibacterials with bacillus Calmette-Guerin viability

      JOURNAL OF UROLOGY
    30. Pfister, C; Flaman, JM; Dunet, F; Grise, P; Frebourg, T
      p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy

      JOURNAL OF UROLOGY
    31. Di Stasi, SM; Giannantoni, A; Massoud, R; Dolci, S; Navarra, P; Vespasiani, G; Stephen, RL
      Electromotive versus passive diffusion of mitomycin C into human bladder wall: Concentration-depth profiles studies

      CANCER RESEARCH
    32. NSEYO UO; DEHAVEN J; DOUGHERTY TJ; POTTER WR; MERRILL DL; LUNDAHL SL; LAMM DL
      PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF PATIENTS WITH RESISTANT SUPERFICIAL BLADDER-CANCER - A LONG-TERM EXPERIENCE

      Journal of clinical laser medicine & surgery
    33. LEBRET T; GAUDEZ F; HERVE JM; BARRE P; LUGAGNE PM; BOTTO H
      LOW-DOSE BCG INSTILLATIONS IN THE TREATMENT OF STAGE T1 GRADE 3 BLADDER-TUMORS - RECURRENCE, PROGRESSION AND SUCCESS

      European urology
    34. SOLOMON LZ; JENNINGS AM; HAYES MC; BASS PS; BIRCH BR; COOPER AJ
      IS GAMMA-LINOLENIC ACID AN EFFECTIVE INTRAVESICAL AGENT FOR SUPERFICIAL BLADDER-CANCER - IN-VITRO CYTOTOXICITY AND IN-VIVO TOLERANCE STUDIES

      Urological research
    35. SOLOMON LZ; JENNINGS AM; SHARPE P; COOPER AJ; BIRCH BR
      INTRAVESICAL CHEMOTHERAPY WITH GAMMA-LINOLENIC ACID BECOMES A REALISTIC PROSPECT IN SERUM-FREE APPLICATIONS - IN-VITRO CYTOTOXICITY AND SYSTEMIC ABSORPTION STUDIES

      The Journal of urology
    36. BUYSE G; WALDECK K; VERPOORTEN C; BJORK H; CASAER P; ANDERSSON KE
      INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION - LESS SYSTEMIC SIDE-EFFECTS DUE TO REDUCED FIRST PASS METABOLISM

      The Journal of urology
    37. BELLDEGRUN AS; FRANKLIN JR; ODONNELL MA; GOMELLA LG; KLEIN E; NERI R; NSEYO UO; RATLIFF TL; WILLIAMS RD
      SUPERFICIAL BLADDER-CANCER - THE ROLE OF INTERFERON-ALPHA

      The Journal of urology
    38. MUNGAN NA; WITJES JA
      BACILLE CALMETTE-GUERIN IN SUPERFICIAL TRANSITIONAL-CELL CARCINOMA

      British Journal of Urology
    39. NSEYO UO; LAMM DL
      IMMUNOTHERAPY OF BLADDER-CANCER

      Seminars in surgical oncology
    40. UCHIDA T; EGAWA S; IWAMURA M; OHKAWA A; ENDO T; KOSHIBA K
      3-DAY INTRAVESICAL INSTILLATION OF ANTICANCER DRUGS FOR PROPHYLAXIS OF BLADDER-CANCER

      Oncology Reports
    41. SERELS S; FLEISCHMANN J
      BIOLOGIC RESPONSE MODIFIERS IN THE MANAGEMENT OF SUPERFICIAL BLADDER-CANCER

      World journal of urology
    42. HUGHES ODM; BISHOP MC; PERKINS AC; FRIER M; PRICE MR; DENTON G; SMITH A; RUTHERFORD R; SCHUBIGER PA
      PRECLINICAL EVALUATION OF COPPER-67 LABELED ANTI-MUC1 MUCIN ANTIBODY C595 FOR THERAPEUTIC USE IN BLADDER-CANCER

      European journal of nuclear medicine
    43. MARTINEZPINEIRO JA; MARTINEZPINEIRO L
      BCG UPDATE - INTRAVESICAL THERAPY

      European urology
    44. CHANG SC; BUONACCORSI G; MACROBERT AJ; BOWN SG
      5-AMINOLEVULINIC ACID (ALA)-INDUCED PROTOPORPHYRIN-IX FLUORESCENCE AND PHOTODYNAMIC EFFECTS IN THE RAT BLADDER - AN IN-VIVO STUDY COMPARINGORAL AND INTRAVESICAL ALA ADMINISTRATION

      Lasers in surgery and medicine
    45. COOKSON MS; HERR HW; ZHANG ZF; SOLOWAY S; SOGANI PC; FAIR WR
      THE TREATED NATURAL-HISTORY OF HIGH-RISK SUPERFICIAL BLADDER-CANCER -15-YEAR OUTCOME

      The Journal of urology
    46. DISTASI SM; VESPASIANI G; GIANNANTONI A; MASSOUD R; DOLCI S; MICALI F
      ELECTROMOTIVE DELIVERY OF MITOMYCIN-C INTO HUMAN BLADDER WALL

      Cancer research
    47. ALIELDEIN B; NABEEH A; ELBAZ M; SHAMAA S; ASHAMALLAH A
      SINGLE-DOSE VERSUS MULTIPLE INSTILLATIONS OF EPIRUBICIN AS PROPHYLAXIS FOR RECURRENCE AFTER TRANSURETHRAL RESECTION OF PTA AND PT1 TRANSITIONAL-CELL BLADDER-TUMORS - A PROSPECTIVE, RANDOMIZED CONTROLLED-STUDY

      British Journal of Urology
    48. HOLLAND AJA; KING PA; CHAUVEL PJ; ONEILL MK; MCKNIGHT DL; BARKER AP
      INTRAVESICAL THERAPY FOR THE TREATMENT OF NEUROGENIC BLADDER IN CHILDREN

      Australian and New Zealand journal of surgery
    49. STENZL A; EDER I; KOSTRON H; KLOCKER H; BARTSCH G
      ELECTROMOTIVE DIFFUSION (EMD) AND PHOTODYNAMIC THERAPY WITH DELTA-AMINOLEVULINIC-ACID (DELTA-ALA) FOR SUPERFICIAL BLADDER-CANCER

      Journal of photochemistry and photobiology.B, Biology
    50. SINGH SS; SMITH KM; BROWN DM
      DRUG RETENTION FOLLOWING INTRAVESICAL DELIVERY OF FLUOROURACIL THERAPEUTIC ADHESIVE IN C3H MOUSE BLADDER

      Anti-cancer drugs
    51. JUNG P; JAKSE G
      BLADDER PRESERVATION IN INVASIVE LOCALLY CONFINED BLADDER-CANCER

      Onkologie
    52. PERNOT M; HUBERT J; GUILLEMIN F; SIX A; HOFFSTETTER S; PEIFFERT D; VERHAEGHE J; LUPORSI E
      COMBINED SURGERY AND BRACHYTHERAPY IN THE TREATMENT OF SOME CANCERS OF THE BLADDER (PARTIAL CYSTECTOMY AND INTERSTITIAL IR-192)

      Radiotherapy and oncology
    53. CREW JP; OBRIEN TS; HARRIS AL
      BLADDER-CANCER ANGIOGENESIS, ITS ROLE IN RECURRENCE, STAGE PROGRESSION AND AS A THERAPEUTIC TARGET

      Cancer metastasis reviews
    54. NSEYO UO; LAMM DL
      THERAPY OF SUPERFICIAL BLADDER-CANCER

      Seminars in oncology
    55. BADALAMENT RA; SCHERVISH EW
      BLADDER-CANCER - CURRENT DIAGNOSTIC METHODS AND TREATMENT OPTIONS

      Postgraduate medicine
    56. NARAYAN P
      TRANSITIONAL-CELL CARCINOMA

      The Journal of urology
    57. LAMM DL; TORTI FM
      BLADDER-CANCER, 1996

      Ca
    58. DANUSER H; SPRINGER JP; THALMANN GN; STUDER UE
      EXPERIENCE WITH INTRAVESICAL INSTILLATION THERAPY USING OXYBUTYNIN HYDROCHLORIDE IN PATIENTS WITH DETRUSOR HYPERREFLEXIA

      Aktuelle Urologie
    59. BOHLE A; BALCK F; VONWIESTERSHEIM J; JOCHAM D
      QUALITY-OF-LIFE AFTER INTRAVESICAL BCG-TH ERAPY

      Aktuelle Urologie
    60. TANAKA H; YOSHIMASA J; FURUKAWA Y; ARAI Y; ARAKI T
      INTRAVESICAL BCG-THERAPY FOR SUPERFICIAL BLADDER-CANCER - ITS EFFECTIVENESS AND ADVERSE-EFFECTS

      Aktuelle Urologie
    61. HYACINTHE LM; JARRETT TW; GORDON CS; VAUGHAN ED; WHALEN GF
      INHIBITION OF BLADDER-TUMOR CELL IMPLANTATION IN CAUTERIZED UROTHELIUM, WITHOUT INHIBITION OF HEALING, BY A FIBRONECTIN-RELATED PEPTIDE (GRGDS)

      Annals of surgical oncology
    62. BUYSE G; VERPOORTEN C; VEREECKEN R; CASAER P
      TREATMENT OF NEUROGENIC BLADDER DYSFUNCTION IN INFANTS AND CHILDREN WITH NEUROSPINAL DYSRAPHISM WITH CLEAN INTERMITTENT (SELF)CATHETERISATION AND OPTIMIZED INTRAVESICAL OXYBUTYNIN HYDROCHLORIDE THERAPY

      European journal of pediatric surgery
    63. VEGT PDJ; DEBRUYNE FMJ; VANDERMEIJDEN APM
      BACILLUS-CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER - CONSENSUS AND CONTROVERSIES

      European urology
    64. ASO Y; AKAZA H; KOTAKE T; TSUKAMOTO T; IMAI K; NAITO S
      PREVENTIVE EFFECT OF A LACTOBACILLUS-CASEI PREPARATION ON THE RECURRENCE OF SUPERFICIAL BLADDER-CANCER IN A DOUBLE-BLIND TRIAL

      European urology
    65. LAMM DL
      BCG IN PERSPECTIVE - ADVANCES IN THE TREATMENT OF SUPERFICIAL BLADDER-CANCER

      European urology
    66. VANDERMEIJDEN APM
      PRACTICAL APPROACHES TO THE PREVENTION AND TREATMENT OF ADVERSE REACTIONS TO BCG

      European urology
    67. SARCIA K; BALTACI S; BEDUK Y; SUZER O; KILIC S; MUFTUOGLU YZ
      EVALUATION OF CELLULAR-IMMUNITY FOLLOWING BACILLUS-CALMETTE-GUERIN THERAPY IN PATIENTS WITH SUPERFICIAL BLADDER-CANCER

      Urologia internationalis
    68. HELLINGER WC; OLDENBURG WA; ALVAREZ S
      VASCULAR AND OTHER SERIOUS INFECTIONS WITH MYCOBACTERIUM-BOVIS AFTER BACILLUS OF CALMETTE-GUERIN THERAPY FOR BLADDER-CANCER

      Southern medical journal
    69. HOLMANG S; HEDELIN H; ANDERSTROM C; JOHANSSON SL
      THE RELATIONSHIP AMONG MULTIPLE RECURRENCES, PROGRESSION AND PROGNOSIS OF PATIENTS WITH STAGES TA AND T1 TRANSITIONAL-CELL CANCER OF THE BLADDER FOLLOWED FOR AT LEAST 20 YEARS

      The Journal of urology
    70. PAVLOTSKY A; EIDELMAN A; BARAK F; WALACH N; HORN Y
      LONG-TERM FOLLOW-UP OF PATIENTS WITH SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE URINARY-BLADDER TREATED BY INTRAVESICAL MITOMYCIN-C

      Journal of surgical oncology
    71. RAITANEN MP; LUKKARINEN O
      A CONTROLLED-STUDY OF INTRAVESICAL EPIRUBICIN WITH OR WITHOUT ALPHA2B-INTERFERON AS PROPHYLAXIS FOR RECURRENT SUPERFICIAL TRANSITIONAL-CELLCARCINOMA OF THE BLADDER

      British Journal of Urology
    72. LAMM DL; RIGGS DR
      IMMUNOTHERAPY OF SUPERFICIAL BLADDER-CANCER

      CLINICAL IMMUNOTHERAPEUTICS
    73. HALL RR
      CURRENT ISSUES IN CANCER .4. SUPERFICIAL BLADDER-CANCER

      BMJ. British medical journal
    74. BARAK M; STEIN A; MECZ Y; LURIE A; GRUENER N
      TNF AND TPS LEVELS IN FOLLOW-UP OF BCG TREATED BLADDER-CANCER PATIENTS

      Journal of tumor marker oncology
    75. CONTI P; REALE M; NICOLAI M; BARBACANE RC; PLACIDO FC; IANTORNO R; TENAGLIA R
      BACILLUS-CALMETTE-GUERIN POTENTIATES MONOCYTE RESPONSES TO LIPOPOLYSACCHARIDE-INDUCED TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1, BUT NOT INTERLEUKIN-6 IN BLADDER-CANCER PATIENTS

      Cancer immunology and immunotherapy
    76. SCHWAIBOLD H; KLINGENBERGER HJ; HULAND H
      LONG-TERM FOLLOW-UP OF CYTOSTATIC INTRAVE SICAL INSTILLATION USING MITOMYCIN-C AND ADRIAMYCIN IN PATIENTS WITH SUPERFICIAL BLADDER-CARCINOMA

      Der Urologe
    77. KALBLE T; BEER M; MENDOZA E; IKINGER U; LINK M; REICHERT HE; FRANGENHEIM T; KLEIN E; FABRICIUS PG
      BCG VERSUS INTERFERON-A FOR RECURRENCE PR OPHYLAXIS OF SUPERFICIAL BLADDER-CARCINOMA - A PROSPECTIVE RANDOMIZED STUDY

      Der Urologe
    78. EROL A; OZGUR S; BASAR M; CETIN S
      TRIAL WITH BACILLUS-CALMETTE-GUERIN AND EPIRUBICIN COMBINATION IN THEPROPHYLAXIS OF SUPERFICIAL BLADDER-CANCER

      Urologia internationalis
    79. NIKU SD; STEIN PC; SCHERZ HC; PARSONS CL
      NEW METHOD FOR CYTODESTRUCTION OF BLADDER EPITHELIUM USING PROTAMINE SULFATE AND UREA

      The Journal of urology
    80. FRIBERG S
      BCG IN THE TREATMENT OF SUPERFICIAL CANCER OF THE BLADDER - A REVIEW

      Medical oncology and tumor pharmacotherapy
    81. OTTO T; GOEPEL M; RUBBEN H
      ADJUVANT LOCAL TREATMENT FOLLOWING CURATIVE TRANSURETHRAL RESECTION OF BLADDER-CARCINOMA

      Onkologie
    82. SCHMITZDRAGER BJ; SCHATTKA SO; EBERT T
      IMMUNOTHERAPY FOR SUPERFICIAL BLADDER-CAN CER

      Der Urologe
    83. KIEMENEY LALM; WITJES JA; HEIJBROEK RP; VERBEEK ALM; DEBRUYNE FMJ
      PREDICTABILITY OF RECURRENT AND PROGRESSIVE DISEASE IN INDIVIDUAL PATIENTS WITH PRIMARY SUPERFICIAL BLADDER-CANCER

      The Journal of urology
    84. DISTASI SM; VIRGILI G; VESPASIANI G; PORENA M; MICALI F
      INTRALESIONAL ALPHA-INTERFERON THERAPY IN PAPILLARY SUPERFICIAL TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - A PILOT-STUDY

      British Journal of Urology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/21 alle ore 02:47:02